2028 Leads Prescription 
Pharmaceutical Technology
MAY 30, 2023
According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028.
World of DTC Marketing
SEPTEMBER 9, 2021
SUMMARY: Allowing Medicare to negotiate drug prices is popular with voters because the media has been focused on the high price of some drugs, but this measure won’t lead to lower healthcare costs. The drug industry is trying to convince voters that government negotiations with drug companies will lead to less innovation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
MARCH 17, 2021
Fierce Pharma just reported, “a big question hanging over AbbVie CEO Richard Gonzalez is whether he can lead the Illinois pharma safely through the patent cliff of its revenue cornerstone Humira. Another biologic, Enbrel, on the market since 1998, will not have its $5 billion in sales challenged until the end of 2028.
PM360
SEPTEMBER 21, 2023
As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program.
Clarivate
OCTOBER 25, 2023
While more expensive than type 2 diabetes drugs, blood thinners follow a similar pattern of high prescription volumes. The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. With 27.5%
Nixon Gwilt Law
MAY 26, 2023
CMS and other payors do not currently pay for these codes , but billing practitioners should continue to submit claims including the codes to provide necessary information that will hopefully lead to more reimbursement opportunities for VR in the future. Telehealth. For information on how Nixon Gwilt helps DTx companies, click here.
Clarivate
MAY 13, 2024
Many insurers use similar networks for Medicaid and exchange plans, so shifting to an exchange plan is less likely to cause a lapse in coverage or abandonment of prescription drugs or maintenance medications that control chronic conditions. Pillo, Senior Healthcare Research and Data Analyst. The post The U.S.
Expert insights. Personalized for you.
105 
Let's personalize your content